Treatments

These posts deal with some the possible treatments for prostate cancer.

Home » Treatments

Brachytherapy a Good Option for Younger Prostate Cancer Patients

Brachytherapy / By / / 1 minute of reading

Brachytherapy (BT) provides excellent long-term outcomes for relatively young men with clinically localized prostate cancer (PCa), researchers reported. In a study of 236 men aged 60 years or younger with clinically localized PCa, BT alone or in combination with external beam radiation therapy (EBRT) was associated with eight-year PSA relapse-free survival (RFS), cancer-specific survival, and overall survival rates of 96%, 99%, and 96%, respectively, according to findings published in BJU International (2013;111:1231-1236). BT-based approaches also were associated with a low risk of long-term genitourinary (GI) and gastrointestinal (GI) morbidities, with erectile function preserved in more than half of patients. Read […]

Brachytherapy a Good Option for Younger Prostate Cancer Patients Read More »

Prostate Cancer AS May Be OK Despite Higher PSA

Active Surveillance / By / / 1 minute of reading

Active surveillance (AS) may be an appropriate management option in carefully selected prostate cancer (PCa) patients with a baseline PSA level of 10 ng/mL or higher, according to study findings presented at the American Urological Association annual meeting. The study showed that these patients are no more likely to experience pathologic progression that patients with lower PSA levels at baseline. Read the article.

Prostate Cancer AS May Be OK Despite Higher PSA Read More »

Focal Therapy for Prostate Cancer Advances

Brachytherapy, Focal Therapy / By / / 1 minute of reading

Laser ablation, cryotherapy, and hemiablative brachytherapy are among the novel approaches that show promise for the focal treatment of localized prostate cancer (PCa), according to studies presented at the 28th annual congress of the European Association of Urology. Most of these treatments are performed under magnetic resonance imaging (MRI) guidance. Read the article.

Focal Therapy for Prostate Cancer Advances Read More »

Focal Therapy Offers Middle Ground for Some Prostate Cancer Patients

Focal Therapy / By / / 1 minute of reading

Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a small insertion and guided into the prostate by magnetic resonance imaging, to burn away cancerous cells in the prostate. Read the article.

Focal Therapy Offers Middle Ground for Some Prostate Cancer Patients Read More »

VIDEO: Dr. Laurence Klotz, “Navigating treatment options for localized prostate cancer”

Videos, Awareness Nights, Active Surveillance, Focal Therapy / By / / 1 minute of reading

  January 2013 Scotiabank Awateness Night Dr.Laurence Klotz, MD, FRCSC Professor, Department of Surgery, University of Toronto Chief, Division of Urology, Sunnybrook Health Sciences Centre Chair, Canadian Uro-Oncology Group and NCIC GU Site Group Editor in Chief (founding), Canadian Journal of Urology Chair, Global GU Oncology Group For localized prostate cancer, the choice of treatment is becoming less straightforward as preferences shift to less aggressive, less intrusive, and increasingly sophisticated approaches. This presentation provides guidance and insight…with focus on active surveillance, focal therapy, MRI imaging, and recent developments in surgery. CLICK ON THE ARROW TO START THE VIDEO  “Navigating treatment

VIDEO: Dr. Laurence Klotz, “Navigating treatment options for localized prostate cancer” Read More »

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective

Advanced Prostate Cancer / By / / 1 minute of reading

Abstract Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have

Recent Developments in Treatments for Metastatic Castration-resistant Prostate Cancer—A Mechanistic Perspective Read More »

VIDEO: Dr. Padrick Warde, “Radiation Therapy for Prostate Cancer in 2012 and beyond.”

Videos, Awareness Nights, Radiation / By / / 1 minute of reading

November 2012 Awareness Night “Radiation Therapy for Prostate Cancer in 2012 and beyond.” Dr. Padrick Warde, MD, MCChB BAO, FRCPC Professor, Department of Radiation Oncology, University of Toronto Staff Radiation Oncologist, The Princess Margaret Cancer Centre/University Health Network Associate Director, Radiation Medicine Program, The Princess Margaret Cancer Centre CLICK ON THE ARROW TO START THE VIDEO Complete Presentation “Radiation Therapy for Prostate Cancer in 2012 and beyond.” High Definition 49inutes Click here to return to top. Click here to return to our main “Videos” page.

VIDEO: Dr. Padrick Warde, “Radiation Therapy for Prostate Cancer in 2012 and beyond.” Read More »

Scroll to Top